Jewish High Tech Community

About the Speakers

Richard Hamilton Gibbs is an entrepreneur in the computer, computer peripheral, media and home entertainment markets currently researching how technological advances are affecting distribution models for music and movies and how adherence to traditional models are damaging the profitability of mainstream entertainment businesses, sabotaging revenues for artists, and alienating consumers based on competition between proprietary and non-proprietary platforms.

Steven W. Fowkes is the Director of the Cognitive Enhancement Research Institute and a co-author of the 1993 book Smart Drugs II. Steve's expertise is the use of generic substances (foods, dietary supplements and patent-expired pharmaceuticals) to treat both "normal" age-related mental decline (e.g., "senior moments" or chronic "brain fog") and overt cognitive diseases (e.g., Down's syndrome and Alzheimer's disease). In 2002, he invented the first of a series of vector-directional polymers with nanostructural self-assembly capabilities, which he is now developing in two startups. He will contrast the divergent developmental challenges with generic vs proprietary technologies to explain why both leave viable solutions sitting unused on the shelf.

Tom Nufert is a co-founding partner with Steve Fowkes in Nanopolymer Systems (the polymer company) and ThioCell (the nanostructured-battery company). Tom was a co-founder of Array BioSciences, which developed a universal spit-on-a-chip bioanalytical system (merging chemistry, biology and physics) and TRC Corporation, which developed chromium-based pharmaceutical treatments for insulin resistance (syndrome X). He has extensive knowledge of self-care treatments for a variety of chronic degenerative conditions ranging from the near-universal-in-America insulin resistance to the #2 and #3 causes of death—heart disease and cancer.